Japan Manufacturing Growth Holds Strong in July Despite Middle East Uncertainty 
Scandinavian Tobacco Group Sells BREAK and Moro Brands to Japan Tobacco for €176 Million 
Gold Price Surges Above $4,100 as Middle East Tensions Boost Safe-Haven Demand 
European Stocks Flat as Oil Tops $100, Trump Tariffs Fuel Inflation Fears 
Volkswagen Cuts 2026 Revenue Outlook as China Weakness, Trade Risks Weigh 
Trump Threatens Iran With 'Major Military Punishment' as Red Sea Attacks Push Oil Above $100 
Asian Stocks Slide as Oil Tops $100, Middle East Conflict Fuels Inflation Fears 
Nasdaq Drops as AI Earnings, Oil Surge and Middle East Tensions Weigh on Wall Street 
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook 
Australia Jobs Surge in June Strengthens Case for More RBA Rate Hikes 
Global Leaders Push Back as Trump Imposes New Forced Labor Tariffs 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
Macquarie Names Greg Ward as CEO, Signaling Stability and Strategic Continuity 
Amkor Stock Surges 17% After $1.5 Billion Nvidia AI Packaging Partnership 
Canada Vows Trade Fight as Trump Imposes 50% Tariffs 
Medipost Co. Ltd, a South Korean biotechnology company, purchased a stake in Canada's OmniaBio Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM), as it is planning to launch its own contract development and manufacturing organization (CDMO) business in North America.
Medipost Co. is planning to make new stem cell treatment products at OmniaBio's facilities in Canada. Thus, it entered into a strategic agreement with the company that is currently a leader in stem cell therapeutics in the world.
The Korean firm engages in the development and manufacturing of stem cell biotech products, and it has acquired a 39.6% stake in OmniaBio Inc. Mediapost is putting in an investment of ₩29.5 billion or around $30 million in Canadian dollars for the purchase. The acquisition deal is set to close on July 1.
According to The Korea Economic Daily, Medipost will be establishing its CDMO business in North America after the deal is completed. It is also planning to raise its stake in OmniaBio by buying convertible bonds worth ₩59.1 billion, and the company is hoping to achieve this by the end of 2024.
With the given numbers, Medipost is set to become the Canadian CDMO firm's largest shareholder, with the total investment reaching C$90 million. OmniaBio's facility is located in Hamilton, Ontario, and it is currently working on a project to expand its facilities for cell and gene therapies from 8,500 square meters to 10,000 square meters site by the year 2025.
"CCRM has spent a great deal of time looking for the right investment partner for OmniaBio, and we are very pleased to have Medipost on board," OmniBio's president, Mitchel Sivilotti, said in a press release. "Medipost will be an initial anchor and revenue generating customer of OmniaBio and will also help us develop an international customer base in Asia. We are launching from a strong and stable position and will be starting construction at McMaster Innovation Park this summer."
Finally, it was revealed that the money from Medipost's purchase deal will be used for the real estate construction and operation of OmniaBio. The overall project was said to be worth $580 million.
